Products - Prostate cancer | Topic

Showing 15 products

Date | Title

Product type: GuidanceRemove ‘Product type: Guidance’ filter
New and updated: New in the last 6 monthsRemove ‘New and updated: New in the last 6 months’ filter

Relugolix for treating hormone-sensitive prostate cancer (TA995)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
14 August 2024
Enzalutamide for treating non-metastatic prostate cancer after radical prostatectomy or radiotherapy (terminated appraisal) (TA994)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
8 August 2024
Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer [ID4004]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
15 January 2025
Apalutamide with gonadotrophin-releasing hormone agonist and radiotherapy for treating high-risk, localised or locally advanced prostate cancer [ID6215]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Abemaciclib with abiraterone acetate and prednisone for treating hormone-relapsed metastatic prostate cancer [ID6230]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Cabozantinib with atezolizumab for treating hormone-relapsed metastatic prostate cancer after 1 hormonal treatment [ID6387]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Degarelix before or with radiotherapy for treating high-risk localised and locally advanced hormone-dependent prostate cancer [ID6419]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Apalutamide with radical prostatectomy for untreated high-risk, localised or locally advanced prostate cancer ID 6471
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Talazoparib with enzalutamide for untreated hormone-sensitive metastatic prostate cancer with a homologous recombination repair mutation ID 6460
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
trublood-prostate for triaging and diagnosing people with prostate cancer symptoms (MT604) (MIB268)
Status:
Topic selection
Programme:
Diagnostics guidance
Expected publication date:
TBC
MT656 Paige Prostate AI system for the detection of prostate cancer
Status:
Topic selection
Programme:
Diagnostics guidance
Expected publication date:
TBC
Stockholm3 blood test for prostate cancer, (MT734),
Status:
Topic selection
Programme:
Diagnostics guidance
Expected publication date:
TBC
Darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer TSID 12045
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Niraparib with abiraterone acetate and prednisone for treating hormone-sensitive metastatic prostate cancer TSID 12044
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Capivasertib with abiraterone for treating hormone-sensitive metastatic prostate cancer with PTEN deficiency ID 6466
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC

Prostate cancer Products

Filter

Product type
1 selected

Guidance programme

Status

New and updated
1 selected

Showing 15 products

Relugolix for treating hormone-sensitive prostate cancer (TA995)

Enzalutamide for treating non-metastatic prostate cancer after radical prostatectomy or radiotherapy (terminated appraisal) (TA994)

Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer [ID4004]

Apalutamide with gonadotrophin-releasing hormone agonist and radiotherapy for treating high-risk, localised or locally advanced prostate cancer [ID6215]

Abemaciclib with abiraterone acetate and prednisone for treating hormone-relapsed metastatic prostate cancer [ID6230]

Cabozantinib with atezolizumab for treating hormone-relapsed metastatic prostate cancer after 1 hormonal treatment [ID6387]

Degarelix before or with radiotherapy for treating high-risk localised and locally advanced hormone-dependent prostate cancer [ID6419]

Apalutamide with radical prostatectomy for untreated high-risk, localised or locally advanced prostate cancer ID 6471

Talazoparib with enzalutamide for untreated hormone-sensitive metastatic prostate cancer with a homologous recombination repair mutation ID 6460

trublood-prostate for triaging and diagnosing people with prostate cancer symptoms (MT604) (MIB268)

MT656 Paige Prostate AI system for the detection of prostate cancer

Stockholm3 blood test for prostate cancer, (MT734),

Darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer TSID 12045

Niraparib with abiraterone acetate and prednisone for treating hormone-sensitive metastatic prostate cancer TSID 12044

Capivasertib with abiraterone for treating hormone-sensitive metastatic prostate cancer with PTEN deficiency ID 6466

Prostate cancer Products

Filter

Product type1 selected

Guidance programme

Status

New and updated1 selected

Showing 15 products

Product type
1 selected

New and updated
1 selected